 BEIJING--BUSINESS WIRE--Genetron Holdings Limited Genetron Health or the Company, NASDAQ:GTH, a leading precision oncology platform company in China that specializes in molecular profiling tests, early cancer screening products and companion diagnostics development, today presented new data and results for HCCscreenTM, a blood-based early screening test for hepatocellular carcinoma HCC. This multi-center prospective study, named the HCCscreenTM Investigational Study HIT, is a co 